Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitors

This page shows the latest JAK inhibitors news and features for those working in and with pharma, biotech and healthcare.

Researchers use AI to identify drugs that could be repurposed for Alzheimer’s

Researchers use AI to identify drugs that could be repurposed for Alzheimer’s

Eli Lilly's JAK inhibitor Olumiant identified as a potential treatment for repurposing. ... JAK inhibitors are commonly used to treat conditions such as rheumatoid arthritis and blood cancers, and block the action of JAK proteins, which play a role in

Latest news

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    JAK inhibitors such as Xeljanz and Rinvoq. ... It faces competition from entrenched generic metformin and sulphonylureas, as well as from more novel drug classes, particularly SGLT-2, inhibitors, DDP4 inhibitors and injectable GLP-1 agonists.

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia. ... and filgotinib’s anticipated launch this year meets

  • Pharma deals during December 2012 Pharma deals during December 2012

    company with an annual cash burn of $30m developing orally active JAK 1 / JAK 2 kinase inhibitors and with a lead product, CYT387, in clinical development and complementary to Gilead's ... YM Bioscience / Gilead. Company acquisition. JAK kinase

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Understanding behaviour change: A Porterhouse Insights specialism
...
Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...